BostonGene to Drive Value-Based Cancer Care Discussions at the 14th Annual AVBCC Summit and Educational Program
BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced its participation in the 14th Annual Association for Value-Based Cancer Care (AVBCC) Summit and Educational Program. The summit, scheduled for October 16 - 18 in New York City, will bring together oncology professionals, payers, and industry leaders to explore the implementation of value-based models aimed at enhancing the quality and cost effectiveness of cancer care. This year’s Summit will focus on multiomic data utilization, biomarker-driven treatment strategies, and the integration of payer metrics to advance value-based practices in oncology.
During the event, BostonGene will participate in two panel sessions:
Utilizing Multiomic Data for Impacting the Quality and Cost of Care
Date & time: Thursday, October 17 | 11:00 AM - 11:50 AM
Speakers:
Mark Hiatt, MD, MBA, MS, Senior Vice President of Market Access and Strategy, BostonGene
Anna Ogloblina, PhD, Senior Director of Market Access and Product Management, BostonGene
This session will explore current guidelines for biomarker assays and their role in informing drug selection and treatment planning for targeted therapies and immunotherapies. The session will also discuss how multiomic testing can be leveraged to monitor treatment response and how industry and payers can collaborate to develop systems that improve the quality and cost effectiveness of oncology care.
Enhancing Payer Quality Metrics through Oncology Screening
Date & time: Thursday, October 17 | 4:00 PM - 4:50 PM
Speaker:
Mark Hiatt, MD, MBA, MS, Senior Vice President of Market Access and Strategy, BostonGene
This discussion will cover the role of various screening assays for pan-cancer and specific cancers, discussing their immediate and long-term impacts on patient outcomes and cost effectiveness. It will also look at how advancements in oncology screening can enhance value-based care in hospital systems and payer networks.
Visit the AVBCC website for more information.
About BostonGene Corporation
BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.
Latest news
